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Abstract
Alternative oxidase (AOX) is a non-mammalian enzyme that can
bypass blockade of the complex III-IV segment of the respiratory
chain (RC). We crossed a Ciona intestinalis AOX transgene into RC
complex III (cIII)-deficient Bcs1lp.S78G knock-in mice, displaying
multiple visceral manifestations and premature death. The
homozygotes expressing AOX were viable, and their median
survival was extended from 210 to 590 days due to permanent
prevention of lethal cardiomyopathy. AOX also prevented renal
tubular atrophy and cerebral astrogliosis, but not liver disease,
growth restriction, or lipodystrophy, suggesting distinct tissue-
specific pathogenetic mechanisms. Assessment of reactive oxygen
species (ROS) production and damage suggested that ROS were
not instrumental in the rescue. Cardiac mitochondrial ultrastruc-
ture, mitochondrial respiration, and pathological transcriptome
and metabolome alterations were essentially normalized by AOX,
showing that the restored electron flow upstream of cIII was suffi-
cient to prevent cardiac energetic crisis and detrimental decom-
pensation. These findings demonstrate the value of AOX, both as a
mechanistic tool and a potential therapeutic strategy, for cIII
deficiencies.
Keywords BCS1L; complex III; GRACILE syndrome; mitochondrial disorder;
respiratory chain
Subject Categories Cardiovascular System; Genetics, Gene Therapy &
Genetic Disease
DOI 10.15252/emmm.201809456 | Received 8 August 2018 | Revised 8 November
2018 | Accepted 12 November 2018 | Published online 10 December 2018
EMBO Mol Med (2019) 11: e9456
See also: A Saada (January 2019)
Introduction
Mitochondrial disorders are the most common class of inherited
errors of metabolism. However, effective treatments are lacking,
and their clinical management remains largely supportive (Pfeffer
et al, 2013). In patients with RC cIII (ubiquinol:cytochrome c
oxidoreductase) deficiency, mutations in several genes encoding
either cIII subunits or assembly factors have been identified. These
compromise cIII enzymatic activity and result in a wide variety of
clinical manifestations (Fernandez-Vizarra & Zeviani, 2015). BCS1L
mutations are the most common cause of cIII deficiency, with vari-
ous neonatal and adult phenotypes described worldwide (Fernan-
dez-Vizarra & Zeviani, 2015), the most severe and prevalent of them
being GRACILE syndrome (fetal growth restriction, aminoaciduria,
cholestasis, liver iron overload, lactic acidosis, and early death
during infancy) (Fellman et al, 1998; Visapa¨a¨ et al, 2002). BCS1L is
a mitochondrial inner membrane translocase required for Rieske
iron–sulfur protein (RISP, UQCRFS1) topogenesis and incorporation
into cIII (Nobrega et al, 1992; Cruciat et al, 1999). Homozygous
Bcs1lc.A232G (Bcs1lp.S78G) knock-in mice bearing the GRACILE
syndrome-analogous mutation recapitulate many of the clinical
manifestations, including growth failure, progressive hepatopathy,
kidney tubulopathy, and, in a C57BL/6JCrlBomTac background,
short survival of 35 days (Leve´en et al, 2011; Kotarsky et al, 2012;
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Rajendran et al, 2016; Purhonen et al, 2017). In the slightly different
C57BL/6JCrl substrain, the homozygotes develop the same early
manifestations but do not succumb to the early metabolic crisis.
This extends their survival to over 150 days (Purhonen et al, 2017)
and brings additional later-onset phenotypes, such as cerebral
astrogliosis (Tegelberg et al, 2017).
Under physiological conditions, quinols that transport electrons
in the mitochondrial inner membrane are efficiently oxidized by cIII,
with electron transfer via cytochrome c and cytochrome c oxidase
(complex IV, cIV) to oxygen (Brand, 2010; El-Khoury et al, 2014).
However, plants and some lower organisms, but not mammals,
express alternative oxidases (AOXs) that transfer electrons directly
from quinols to oxygen without proton translocation. Their main
role is to maintain electron flow when the cIII-cIV segment of the
RC is impaired, limiting production of ROS and supporting redox
and metabolic homeostasis (McDonald & Vanlerberghe, 2004;
El-Khoury et al, 2014). Ciona intestinalis AOX has been cloned and
expressed in human cultured cells (Hakkaart et al, 2006), fruit flies
and mice (El-Khoury et al, 2013; Szibor et al, 2017). In these
models, AOX is inert under non-stressed conditions, most likely
because it accepts electrons only when the quinone pool is highly
reduced (Hoefnagel & Wiskich, 1998; Castro-Guerrero et al, 2004),
such as under inhibition or overload of cIII or cIV (Dassa et al,
2009). Accordingly, upon inhibition of cIII or cIV by mutations or
chemical inhibitors, ectopic AOX can maintain respiration and
prevent cell death (Dassa et al, 2009; Fernandez-Ayala et al, 2009).
We set out to test whether AOX expression could prevent the detri-
mental effects of cIII deficiency in a mammalian model, by restoring
electron flow upstream of cIII. To this end, we crossed mice carrying
a broadly expressed AOX transgene (Szibor et al, 2017) with the
Bcs1lc.A232G mice and assessed disease progression, organ manifesta-
tions, and metabolism in the homozygotes with and without AOX
expression.
Results
Broadly expressed AOX triples the life span of cIII-deficient
Bcs1lp.S78G mice
To assess the effect of cIII bypass on the survival and tissue mani-
festations in cIII-deficient mice, we bred cohorts of wild-type and
Bcs1l mutant mice with or without a Ciona intestinalis AOX trans-
gene. Hereafter, we will refer to the Bcs1lp.S78G homozygotes as
GRAC (as an abbreviation of GRACILE syndrome) mice. The
Bcs1lp.S78G homozygotes carrying AOX transgene will be referred to
as GROX mice (GRAC + AOX). Figure 1A shows a timeline of the
appearance of the previously reported and novel phenotypes in
GRAC mice, as well as the assessments included in this study. The
GRAC mice reached the criteria of euthanasia between postnatal day
180 (P180) and P220, with median survival to P210 (Fig 1B). In
contrast, the GROX mice showed no signs of terminal deterioration
or spontaneous deaths at P200 and survived to a median age of
590 days (Fig 1B). To assess whether the extended survival was
due to an overall improvement in energy metabolism, we measured
growth, whole-body metabolism, and body composition in young
adult mice. The GRAC mice were growth restricted (Fig 1C and E)
and had increased lactate-to-glucose ratio (Fig 1D), low fat mass
(Fig 1F), bone density (Fig 1G), and heat production (Fig 1H) and,
in females, low respiratory exchange ratio (Fig 1I). Unexpectedly,
AOX had no or only small effect on these parameters (Fig 1C–I),
suggesting that the AOX-mediated extension of survival depended
on a tissue or cell-type specific pathology rather than whole-body
energy metabolism.
AOX permanently prevents lethal cardiomyopathy and alleviates
renal and cerebral manifestations
Histopathological analysis of autopsy samples from end stage
(P200) mice showed two novel phenotypes not previously reported
in studies of younger GRAC mice: cortical kidney atrophy and
cardiomegaly with dilated ventricles (Fig 2A and B). Fibrosis was
prominent in liver, kidney, and heart (Fig 2C and D). Suspecting
cardiomyopathy as the cause of death, we assessed cardiac func-
tions at several time points. Echocardiography showed minimal
functional changes at P150 (Fig EV1A–F), but severe dilated
cardiomyopathy, focal fibrosis, decreased ejection fraction, and
fractional shortening at P200 (Fig 2A and F), indicating end-stage
cardiomyopathy. Strikingly, the GROX littermates had normal
heart size (Fig 2A and B), no fibrosis (Fig 2C and D), and overtly
normal cardiac function (Fig 2E and F), explaining their extended
survival. mRNA expression of key markers for cardiac hypertrophy
and fibrosis was significantly altered already in the presymp-
tomatic (P150) GRAC hearts, and these changes were largely
prevented in the GROX mice (Fig 2G). A kidney stress test with
salt-enriched (6% w/w) chow starting at P150 had no effect on
cardiac function at P200, or on survival, and blood pressure was
only increased at the end stage in the salt-fed mice when compared
to P150 baseline (Fig EV1A–F), consistent with a primary
cardiomyopathy. Remarkably, the GROX mice had normal-sized
and non-fibrotic heart throughout their life span, to over P600
(Fig EV2A–D).
Kidneys of GRAC mice showed proximal tubulopathy with
fibrosis (Fig 2C and D) and tubular degeneration (decreased tubu-
lar mass) at P200 (Appendix Fig S1). In GROX mice, the kidney
mass and apparent tubular volume were preserved (Fig 2A and
B). On the basis of the proliferation marker Ki67 and apoptosis
marker cleaved caspase-3, this was likely due to decreased apop-
tosis rather than increased regeneration (Appendix Fig S1I and
J). However, AOX had only minor effect on other histological
lesions (Appendix Fig S1A–G) or functional parameters: albumin-
uria, hematuria, and urinary creatinine (Fig 2H and I,
Appendix Fig S1H). At P600, the kidneys were severely fibrotic
but still of normal size, indicating long-term protection from
tubular atrophy (Fig EV2A, B and D). Surprisingly, AOX had no
effect on the liver fibrosis (Fig 2C and D) or the elevated liver
enzymes (Fig 2J and K) at end stage. The cause of death of the
GROX mice remains unknown, but eventual deterioration due to
the progressing kidney and liver disease is an obvious possible
explanation.
GRACILE syndrome patients have no encephalopathy, but the
brains of GRAC mice show peculiar focal astrogliosis in the primary
barrel field of the somatosensory cortex (S1BF) (Tegelberg et al,
2017). Staining for glial fibrillary acidic protein (GFAP) showed that
the astrogliosis was almost fully prevented by AOX at P200
(Fig 3A).
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Figure 1. AOX expression prolongs the survival of cIII-deficient Bcs1lp.S78G mice without affecting growth or whole-body metabolism.
A Schematic presentation of the multiorgan manifestations, described in this study or previously, in homozygous Bcs1lc.A232G (GRAC) mice, and the time points of the
investigations performed in this study.
B Survival curves of homozygous Bcs1l mutant mice without (GRAC) and with (GROX) alternative oxidase (AOX) expression (n = 18–21/group). The median survival of
GRAC mice was 210 days and of GROX mice was 589 days with no gender difference.
C Weight of mice from P50 to P200 (n > 10/group) and at P600 (n = 4–6/group).
D Blood lactate-to-glucose ratio at P200 (n = 8/group).
E–G Dual-energy X-ray absorptiometry (DEXA) analysis (n = 10/group) of (E) lean mass, (F) fat mass, and (G) bone mineral density at P98.
H, I Indirect calorimetric measurement (n = 10/group) of (H) heat production and (I) respiratory exchange ratio at P77.
Data information: The survival data were analyzed using log-rank (Mantel–Cox) test (P < 0.0001). Bar graphs represent mean  SD. The data (D–I) were analyzed using
Kruskal–Wallis and Mann–Whitney U-tests for selected comparison. Significant differences between groups (P-value) are indicated on graphs.
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AOX preserves mitochondrial ultrastructure in rescued tissues
Previous studies have shown disrupted hepatic mitochondrial
ultrastructure in younger Bcs1l mutant mice (Leve´en et al, 2011;
Purhonen et al, 2017). In the P150 GRAC mice, electron microscopy
showed abnormal mitochondrial ultrastructure in hepatocytes as
well as in kidney tubular cells, and, importantly, in cardiomyocytes
already at onset of the cardiomyopathy (Fig 3B). The mitochondria
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Figure 2.
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were smaller and contained fewer cristae, which were thicker than
in WT mitochondria. AOX fully or partially prevented these changes
in cardiomyocytes and kidney tubular cells, but not in hepato-
cytes, (Fig 3C–F), correlating faithfully with the rescue of tissue
pathology.
AOX relieves cardiac metabolic stress and
prevents decompensation
Seeking a mechanism for the remarkably tissue-specific rescue
effects of AOX, we performed transcriptomics and metabolomics
at P150, at the onset of the cardiomyopathy. The three affected
tissues showed marked global transcriptional changes, including
in the GRAC heart despite it being functionally normal at this
stage (Fig 4A–C). In correlation with the histological findings,
AOX normalized the expression of only few genes in the liver,
but of about 25% of dysregulated genes in the kidney and about
50% in the heart (Appendix Fig S2A–C). The most robustly
upregulated gene sets were related to extracellular matrix organiza-
tion, a signature of tissue remodeling and fibrosis (Fig 4D–F,
Appendix Table S1), and cell cycle in liver and kidney, but not in
the heart (Fig 4D–F) reflecting differential regenerative capacity of
these tissues. As expected, energy metabolism-related gene expres-
sion was altered in all three tissues (Fig 4D–F, Appendix Fig S2D).
Alternative oxidase almost fully prevented these changes in heart,
but not in kidney or liver (Fig 4D–F). Notably, AOX had a signifi-
cant effect on gene expression in the Bcs1l wild-type heart, includ-
ing upregulation of genes related to mitochondrial function
(Fig 4D, G, I and Appendix Fig S2D). Expression of the major
cardiac metabolic regulator HIF-1a and the metabolic stress-indu-
cible transcriptional regulators ATF3 and ATF4 (Kalfon et al,
2017; Quiros et al, 2017) was elevated in GRAC hearts and
normalized by AOX (Fig 4J and K), indicating relieved metabolic
stress. Upregulation of PGC-1a, the master regulator of mito-
chondrial biogenesis, and the mitochondrial transcription factor
TFAM, in the GRAC heart suggested an attempt for compen-
satory mitochondrial biogenesis (Fig 4G–I). However, Western
blot analysis using the abundance of RC complex subunits as a
proxy showed no significant changes in mitochondrial mass
between the groups (Fig EV3I) in any tissue. We previously
identified an upregulated set of genes, which we designated cIII
stress signature, in P45 Bcs1l mutant livers (Purhonen et al,
2017). This gene set was also highly upregulated in all three
GRAC tissues. Despite rescue of kidney tubular mass, AOX
amplified the cIII stress signature specifically in this tissue, but
not in the heart or liver (Fig 4L).
Alternative oxidase is under the strong synthetic CAG promoter
and expressed in all tissues in the Rosa26AOX mice (Szibor et al,
2017). In our mice, AOX mRNA expression was similar in heart and
liver and somewhat lower in kidney (Fig EV3H). In total tissue
lysates from the AOX mice, the amount of AOX protein was consider-
ably higher in heart than in liver or kidney (Fig EV3H). However,
this difference was mainly due to the higher mitochondrial mass in
heart, as shown by the mitochondrial loading control VDAC1 and
also by most respiratory chain subunits (Fig EV3I). Interestingly, the
amount of AOX protein was affected by the Bcs1l mutation (AOX vs.
GROX mice) so that the amount in the three GROX tissues was almost
identical (Fig EV3H), which essentially rules out that the differences
in rescue would be due to different levels of AOX expression.
The metabolomics revealed only modest cardiac metabolite
changes at the onset (P150) of the cardiomyopathy (Fig 5A,
Appendix Table S2). Nevertheless, several three-carbon glycolytic
intermediates were depleted, and these tended to be normalized by
AOX (Fig 5A). In line with this, the gene expression of PPAR-1a, the
major driver of fatty acid utilization, was downregulated in GRAC but
normal in GROX heart (Fig 4G). The TCA cycle metabolites malate
and fumarate, adenylate energy charge, and NADH/NAD+ ratio,
which all could be affected by both the cIII blockade and AOX, were
not changed in the GRAC or GROX heart tissue (Fig 5C–F). Interest-
ingly, the amino acid proline, which has been long known to accu-
mulate in conditions with lactic academia (Kowaloff et al, 1977), was
below detection limit in WT heart but increased to approximately
200 nmol/g in GRAC heart. The proline accumulation was partially
prevented by AOX (Fig 5G). Concurrently, glutamate, the biosyn-
thetic precursor of proline, was decreased to about 50% in GRAC
mice and normalized to WT level in GROX heart tissue (Fig 5A). The
mRNA levels of glutamate c-semialdehyde synthetase (P5CS,
ALDH18A1) and pyrroline-5-carboxylate reductase 1 (P5CR, PYCR1),
both driving proline synthesis from glutamate, were upregulated 1.8-
fold and 1.7-fold, respectively, in the GRAC heart (Fig 5H and I).
Targeted metabolomics of liver tissue (Fig 5B, Appendix Table S2)
showed significant metabolite changes characteristic of failing energy
metabolism and glycogen depletion, as previously shown in juvenile
mice (Kotarsky et al, 2012). These included decreased hexose phos-
phates, several other glycolytic intermediates, acetyl-CoA and NAD+,
and elevated TCA cycle intermediates and amino acids, the latter
suggesting protein degradation for fuel. NADH/NAD+ ratio was
increased (Fig 5F), in line with our previously published data show-
ing decreased hepatic NAD+ (Purhonen et al, 2018). Proline level
was not changed in liver (Appendix Table S2). Alternative oxidase
had only a minor effect on the hepatic metabolite levels (Fig 5B, E,
and F).
◀ Figure 2. AOX prevents lethal cardiomyopathy and progression of renal tubulopathy to kidney atrophy.A Hematoxylin–eosin-stained cross sections of heart and kidney at P200.
B Weight of heart and kidney at P200 (n = 4/group).
C, D Sirius Red staining (C) for fibrosis in liver, heart, and kidney at P200, and (D) quantification of fibrosis in myocardium, kidney cortex, and liver (n = 5–7).
E, F Echocardiography data (n = 4–6/group) showing (E) ejection fraction (EF) and fractional shortening (FS). (F) Systolic (LV Vol;S) and diastolic (LV Vol;D) left ventricle
volume in mice.
G Expression of cardiac hypertrophy and fibrosis-associated genes in the presymptomatic (P150) heart (n = 6/group).
H, I 24-h excretion of (H) albumin and (I) creatinine in urine at P200 (n = 4/group).
J, K Liver enzymes (J) alanine aminotransferase (ALT) and (K) alkaline phosphatase (ALP) in plasma at P200 (n = 8/group).
Data information: Bar graphs represent mean  SD. Statistics: one-way ANOVA followed by Tukey’s test (for graphs B, D, G, H, J, and K), one-way ANOVA followed by
unpaired t-test with Welch’s correction (for graphs E and F), and Mann-Whitney U-tests (for graph I).
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Figure 3. AOX ameliorates cerebral astrogliosis and maintains mitochondrial ultrastructure in rescued tissues.
A GFAP staining for cerebral astrocytes. The barrel field of the primary somatosensory cortex (S1BF) is highlighted with brackets.
B Mitochondrial ultrastructure in cardiomyocytes, kidney tubular cells, and hepatocytes at P200 as visualized by electron microscopy. Scale bar 1 lm.
C–F (C) Average cross-sectional area of mitochondrion, (D) number of cristae per mitochondrion, (E) crista thickness, and (F) average distance between cristae in
mitochondria (n = 3 mice/group).
Data information: Bar graphs represent mean  SD. Statistics for graphs (C–F): one-way ANOVA followed by Tukey’s test.
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Figure 4. AOX mitigates cardiac, but not hepatic or renal, metabolic stress-related gene expression changes.
A–C Principal component analysis of transcriptome data from (A) heart, (B) kidney, and (C) liver.
D–F Heat map visualization of pathway enrichment analysis (Reactome database). Full pathway analysis is provided in Appendix Table S1. Benjamin–Hochberg FDR-
corrected P-values are color labeled as indicated for the three comparisons.
G–K Gene expression of major transcriptional regulators of energy metabolism (PPAR-a, HIF-1a), mitochondrial biogenesis (PGC-1a, TFAM), and stress responses (ATF4)
in heart at P150 (n = 6/group).
L Expression of cIII stress signature genes in heart, kidney, and liver (n = 6/group). Error bars represent 95% confidence interval of mean difference.
Data information: Box plots (G–K) represent quartiles, maximum value, and minimum value (relative fold change “FC” to WT). Statistics: one-way ANOVA followed by
Tukey’s test.
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Figure 5. AOX has little effect on cardiac energy metabolites but attenuates proline accumulation at onset of disease.
A Significantly altered metabolites (FDR < 0.2; P < 0.05, n = 5/group) in presymptomatic (P150) heart tissue of GRAC (red) and GROX (green) mice.
B Significantly altered metabolites (FDR < 0.2; P < 0.05, n = 5/group) in liver tissue of GRAC (red) and GROX (green) mice.
C–F Concentrations of the TCA cycle intermediates (C) fumarate and (D) malate, (E) adenylate energy charge, and (F) NADH/NAD+ ratio (n = 5/group).
G–I (G) Proline concentration in heart tissue at P200 (# below detection limit) and mRNA expression of proline synthesis-related genes (n = 6/group) (H) Aldh18a1 and
(I) Pycr1 at P150.
Data information: Bar graphs (A–G) represent mean  SD, and box plots of mRNA expressions represent quartiles, minimum value, and maximum value (relative fold
change “FC” to WT). Statistics for graphs (A, B, F, and H): one-way ANOVA followed by Tukey’s test.
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AOX restores cardiac mitochondrial respiration
To investigate whether the AOX rescue effect was linked to
improved RC assembly and function, we first performed blue native
gel electrophoresis (BNGE) analyses. These confirmed the loss of
RISP from free cIII dimer (cIII2) and from the cI-cIII2 supercomplex
(SC1) in GRAC tissues (Fig 6A). Surprisingly, the amount of this
fully assembled cIII2 was significantly increased in the GROX heart
when compared to GRAC (Fig 6B and C). In the GROX liver and
kidney, the change was opposite, with lower amount of RISP in cIII2
(Fig 6B and C).
Spectrophotometrically measured cIII activity in isolated mito-
chondria was decreased to < 50% of WT values in all three tissues
at P150, a threshold for the appearance of hepatic pathology in juve-
nile mice (Leve´en et al, 2011). Despite that AOX should theoreti-
cally not affect cIII activity, it was partially restored in GROX heart
mitochondria (Fig 6F), in line with the improved RISP assembly.
The activities of cI, cII, and cIV were unchanged in heart and liver
(Fig 6D, E and G).
Respirometry confirmed AOX-mediated respiration in all three
GROX tissues at P150, as measured using the AOX inhibitor n-propyl
gallate (nPG). Respiration did not respond to nPG in AOX mice
(with wild-type Bcs1l and normal cIII activity), which indicates that
AOX was catalytically active only in the mutants (Fig 6H). The cIII
dysfunction did not limit state 3 respiration of liver and kidney mito-
chondria (Fig 6I and J) when driven by cI-linked substrates (malate,
pyruvate, and glutamate to generate NADH), but clearly did so in
the heart (Fig 6I). Further stimulation of respiration through cII by
addition of succinate revealed cIII deficiency in all three tissues in
GRAC mice, with the most severe effect in the heart (Fig 6J).
Remarkably, cI- and cII-linked state 3 respiration (malate, pyruvate,
glutamate, and succinate at ADP saturation) were rescued to wild-
type level in GROX heart mitochondria (Fig 6I and J). A similar
effect was found in state 3 respiration of heart and liver at P200
(Fig EV4A and B).
AOX does not affect ROS damage or defense but normalizes
cardiac NO-related gene expression
Limiting excessive ROS production from the RC has been posited as
a major mechanism of action of AOX (El-Khoury et al, 2014). To
assess ROS production in the affected GRAC tissues, we measured
hydrogen peroxide (H2O2) emission from isolated mitochondria at
P150. The Amplex Red-peroxidase assay showed that total H2O2
emission was decreased in GROX heart and kidney as compared to
GRAC (Fig 7A). However, analysis of gene expression related to
ROS defense and damage showed that glutathione synthesis and
conjugation were upregulated only in the GRAC liver (Fig 7B) and
were not affected by AOX. GRAC hearts showed no upregulation of
ROS defense at all (Fig 7B) despite the most severe cIII dysfunction.
Total tissue glutathione was not changed in GRAC heart or liver but
was increased in both GROX tissues (Fig 7C). Mitochondrial aconi-
tase activity, a sensitive marker of ROS damage to iron–sulfur clus-
ters (Yan et al, 1997), and protein carbonylation (Fig EV4C and D)
were not significantly different between the genotypes. Urinary
isoprostanes, a marker of systemic oxidative stress (Fig 7D), was
elevated in both GRAC and GROX. Immunohistochemical staining
for the lipid peroxidation product 4-hydroxynonenal was increased
in all three GRAC tissues, but the increase was not prevented by
AOX (Fig 7E and F). Finally, we fed the GRAC mice the mitochon-
dria-targeted ROS scavenger mitoQ, which has shown beneficial
effects in mouse models of cardiac ischemia–reperfusion injury
(Adlam et al, 2005). MitoQ feeding started at P150 had no effect on
the survival of the mice by P200 or on their cardiac function
(Fig EV1A–F).
Since ROS damage was clearly not instrumental in the cardiac
rescue by AOX, we looked at nitric oxide (NO) metabolism that is
particularly important in the cardiovascular system and known to
interact chemically with ROS and the respiratory chain (Carnicer
et al, 2013). We observed a significant increase in NO signaling-
related gene expression specifically in GRAC hearts, and these
changes were attenuated by AOX (Fig 8A). Decreased mRNA expres-
sion of central targets of NO signaling, ryanodine receptor (RyR2),
sarco(endo)plasmic reticulum Ca2+-ATPase Serca2 (Atp2a2), and
phospholamban (Pln) in GRAC heart suggested decreased cardiac
contraction-related Ca2+ channel function (Fig 8B–D). AOX upregu-
lated these Ca2+ channel genes in both Bcs1l mutant and wild-type
mice. Expression of endothelial NO synthase (Nos3) was increased in
GRAC heart (Fig 8E), and, most strikingly, expression of neuronal
NO synthase (nNos, Nos1) was increased over 10-fold in the GRAC
heart with a significant attenuation in GROX mice. Western blot anal-
ysis confirmed similar upregulation of NOS1 protein (Fig 8F and G).
Increased gene expression of dimethylarginine dimethylaminohydro-
lase 1 (Ddah1), which hydrolyzes the endogenous NOS inhibitors
dimethylarginine and monomethylarginine (Fig 8H), and increased
product/substrate (citrulline/arginine) ratio (Fig 8I) in GRAC heart
suggested increased NO production. However, neither protein nitroty-
rosine nor total nitrites were increased in the GRAC hearts (Fig 8J
and K).
Discussion
Here, we show that AOX, a non-mammalian enzyme that can
bypass cIII blockade by shunting electrons directly from the quinone
pool to oxygen, is able to permanently prevent lethal cardiomyopa-
thy and alleviate multiple other pathologies in cIII-deficient GRAC
mice. The GRAC mice, initially bred in C57BL/6JBomTac back-
ground (Leve´en et al, 2011), have turned out particularly useful in
mechanistic and interventional studies (Rajendran et al, 2016;
Purhonen et al, 2017, 2018) due to their postnatal symptom-free
period and short survival. In the current study, we found that, in
the C57BL/6JCrl background, the homozygotes survive to median
P210 and develop lethal cardiomyopathy after P150, a manifesta-
tions not seen in the GRACILE syndrome patients with early neona-
tal lethality, but a common manifestation in other mitochondrial
disorders. AOX provided a full functional rescue of the cardiomy-
opathy, restored cI- and cII-linked respiration to wild-type levels,
and abrogated the signature of metabolic stress responses. Heart
muscle is highly dependent on mitochondrial respiration and oper-
ates at constant ATP and phosphocreatine concentrations (Ventura-
Clapier et al, 2011; Guzun et al, 2015). Our results clearly indicate
that the pathogenesis mechanism leading to cardiomyopathy in
GRAC mice is insufficiency of electron flow, resulting in disturbed
redox and metabolic homeostasis. Cardiac hypertrophy and a meta-
bolic switch from fatty acid to glucose utilization are hallmarks of
ª 2018 The Authors EMBO Molecular Medicine 11: e9456 | 2019 9 of 19
Jayasimman Rajendran et al AOX rescues cIII deficiency in mice EMBO Molecular Medicine
Published online: December 10, 2018 
AB C D E
F G H
I J
Figure 6. AOX modifies RISP assembly and rescues mitochondrial respiration in tissue-specific fashion.
A Blue native PAGE analysis of RISP and CORE1 assembled into free cIII2 and supercomplexes (SCs).
B, C RISP per CORE1 ratio in (B) SC1 and (C) free cIII2 (n = 3/group).
D–F Spectrophotometric assay of (D) cI, (E) cII, and (F) cIII activity in isolated mitochondria at P200 (n = 4–6/group).
G cIV activity as measured using an oxygraph (n = 7/group).
H n-Propyl gallate-sensitive AOX-mediated cI- and cII-linked state 3 respiration in AOX and GROX mice (n = 7/group, Mann-Whitney U-test).
I, J cI-linked (I), and cI- and cII-linked (J) state 3 respiration in isolated heart, kidney, and liver mitochondria (n = 8/group). We used malate, pyruvate, and glutamate to
generate NADH for the cI. Subsequently, we added the cII substrate, succinate, to obtain cI- and cII-linked respiration in the presence of saturating ADP.
Data information: Bar graphs represent mean  SD. Statistics: one-way ANOVA followed by Tukey’s test. Significant differences between groups (P-value) are indicated
on graphs.
Source data are available online for this figure.
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Figure 7. AOX normalizes ROS production by isolated mitochondria but has little effect on ROS markers in tissues.
A Amplex Red-based detection of H2O2 emission, a surrogate for respiratory chain-derived ROS, during cI- and cII-linked state 3 respiration (n = 6/group).
B Gene expression related to ROS scavenging.
C Total glutathione in heart and liver tissue (n = 5/group).
D Urinary isoprostanes per creatinine as a measure of oxidative stress (n = 4/group).
E, F Representative images (E) of tissue sections immunostained with an antibody against 4-hydroxynonenal (4-HNE), a lipid peroxidation marker. (F) Quantification of
the 4-HNE immunostaining.
Data information: Bar graphs represent mean  SD. Statistics: Mann–Whitney U-test (graph D) and one-way ANOVA followed by Tukey’s test (graphs A and C).
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Figure 8. AOX normalizes cardiac nitric oxide-related gene expression.
A Heat map visualization of the expressions of selected nitric oxide (NO)-related genes.
B–E Gene expression of Ca2+ channel genes (B) ryanodine receptor, RYR2, (C) sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2 or ATP2A2), (D) phospholamban (PLN),
and (E) endothelial nitric oxide synthase NOS3 (n = 6/group).
F, G Expression of neuronal nitric oxide synthase (NOS1) mRNA (F) and (G) protein with a representativeWestern blot. WT brain was used as positive control in the first lane (G).
H Cardiac gene expression of dimethylarginine dimethylaminohydrolase 1 (DDAH1) (n = 6/group).
I Cardiac citrulline-to-arginine ratio (n = 5/group).
J Cardiac protein nitrotyrosine quantified from Western blots (n = 6/group).
K Nitrite concentration in heart tissue (n = 4/group).
Data information: Box plots for mRNA expression (B–E and H) represent quartiles, minimum value, and maximum value (relative fold change “FC” to WT). Bar
graphs (F, I, and K) and scatter plot (J) represent mean  SD. Statistics: one-way ANOVA followed by Tukey’s test (for graphs B–F, H, and I). Significant differences
between groups (P-value) are indicated on graphs.
Source data are available online for this figure.
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an adaptive response to chronic stress (Hansson et al, 2004;
Ventura-Clapier et al, 2011; Tuomainen & Tavi, 2017), reflected in
the GRAC mice by depletion of glycolytic intermediates, downregu-
lation of PPAR-a, and the upregulation of ATF4 (Quiros et al, 2017),
PGC-1a, and TFAM. These changes were fully or partially prevented
in GROX mice, further implying that the underlying metabolic stress
was relieved. The surprising partial rescue of cIII assembly and
activity by AOX in cardiac mitochondria was similar to what we
observed in liver mitochondria upon attenuation of hepatopathy by
ketogenic diet (Purhonen et al, 2017) and could be secondary to the
general improvement in mitochondrial structure and function.
GRACILE syndrome patients and GRAC mice display proximal
kidney tubulopathy (Fellman et al, 1998; Leve´en et al, 2011), which
we found to progress to kidney atrophy in the older mice. Tubular
epithelial cells have a high energy demand, are rich in mitochon-
dria, and thus susceptible to damage from RC dysfunction (Emma
et al, 2012). The typical atrophic changes in the GRAC kidney were
efficiently prevented, and tubular mass was preserved by AOX
during the entire life span of the GROX mice. However, the compro-
mised cI- and cII-linked respiration and pathological gene expres-
sion changes were not improved in samples prepared from the
whole kidney, which suggest that the cIII bypass mainly affected a
limited cell population, most likely the tubular epithelial cells.
Surprisingly, AOX provided no long-term histological or func-
tional benefit in the liver. Correspondingly, it did not correct the
early-onset systemic manifestation growth restriction and lipodys-
trophy, which are likely dependent on the liver. Even though ex vivo
oxygen consumption at saturating substrate concentration showed
that AOX was able to support respiration in liver mitochondria, this
conferred no functional improvement in liver. One explanation
would be that the metabolic threshold for AOX activation was not
passed in the liver in vivo. Indeed, loss of cIII activity and phospho-
rylating respiration were not as prominent in the liver as in the
heart. The apparent further loss of RISP from cIII in the presence of
AOX could simply reflect relaxation of the need to keep cIII assem-
bled and running when AOX replaces its ubiquinol oxidase activity.
It is also possible that disturbances in the numerous anabolic and
catabolic functions of hepatic mitochondria contribute to the patho-
genesis in this tissue, but are not affected by the cIII bypass. Finally,
AOX transgene expression was somewhat different in different
tissues, as shown in this study and previously (Szibor et al, 2017),
but this did not correlate with the rescue effect in the tissues we
studied. Thus, the disparity in AOX rescue effect was likely due to
differences in the severity of the respiration defect in different
tissues.
Respiratory chain blockade may lead to increased ROS produc-
tion via electron leak to oxygen (Murphy, 2009; Brand, 2010).
Although loss of RISP inactivates the quinol oxidation site of cIII
and thus should decrease rather than increase ROS, cIII dysfunction
may lead to ROS production at cI and cII (Korde et al, 2011; Sena
et al, 2013). Indeed, we observed increased ROS production in
GRAC heart and kidney mitochondria, and this was prevented by
AOX. Increased ROS may cause oxidative damage to proteins and
other molecules, which, in turn, should invoke a protective detoxifi-
cation response. However, expression of glutathione peroxidases
and glutathione-S-transferases was induced only in the GRAC liver.
In the heart and kidney, apart from locally increased lipid peroxida-
tion, there were no consistent signs of ROS damage or detoxification
response. The lack of transcriptional response to oxidative damage
was particularly striking in the GRAC heart, ruling this out as a
significant early pathogenetic mechanism, although it may still play
a role in end-stage disease. Dogan et al (2018) recently reported that
AOX expression in a Cox15 knock-out model of cIV deficiency exac-
erbated myopathy and decreased survival. Harmful perturbation of
redox signaling via AMPK/PGC-1a was suggested as a mechanism.
Interestingly, AOX did not worsen any of the multiple visceral and
systemic phenotypes we thoroughly investigated in the cIII-deficient
GRAC mice. Neither did we observe worsening in any behavioral or
motor activity parameters (our behavioral scoring and additional
unpublished phenotyping data from the German Mouse Clinic) that
could have suggested development of skeletal myopathy, not other-
wise present in GRAC mice, upon AOX expression. Moreover, feed-
ing GRAC mice the mitochondria-targeted antioxidant mitoQ had no
effect on the progression of cardiomyopathy. Compound heterozygous
or homozygous missense mutations in COX15 have been identified in
patients presenting with cardiomyopathy and/or encephalopathy, but
not skeletal myopathy (Alfadhel et al, 2011). Whether the findings of
Dogan et al (2018), showing adverse effect of AOX expression in the
mice with Cre-mediated skeletal muscle-specific Cox15 knock-out,
apply to other models of cIV deficiency and/or mitochondrial myopa-
thy remains to be investigated. Nevertheless, given that we found
obvious differences in the response to AOX-mediated cIII bypass in
different tissues in our model, it is possible that the responses would
be disparate in other models, depending on the exact nature of the
mutation and respiration defect.
We found that NOS1, an enzyme generating NO, a major modu-
lator of cardiac function and calcium fluxes (Pechanova et al,
2015), was highly upregulated specifically in the GRAC heart, and
this was to large extent prevented in GROX hearts. NOS1 and NOS3
upregulation was accompanied by changes in NO- and Ca2+ chan-
nel-related gene expression, both alleviated by AOX. NO itself is
relatively inert but reacts rapidly with superoxide, the primary ROS
emitted by the RC, forming highly reactive and cytotoxic peroxyni-
trite (Pechanova et al, 2015). Peroxynitrite can impair cardiac func-
tion via multiple mechanisms, including inhibition of cI and cIV by
S-nitrosation and nitrosylation, respectively (Burwell & Brookes,
2008; Chouchani et al, 2013; Pechanova et al, 2015), which in the
case of GRAC mice could exacerbate the cardiomyopathy via a
vicious circle-type mechanism. However, cIV activity was similar in
all groups and lack of increased protein tyrosine nitration and total
nitrates suggests NOS uncoupling or loss of function despite highly
increased expression, rather than increased NO production in the
GRAC heart. These findings imply that impaired NO metabolism
should be further investigated as a pathological process in mito-
chondrial cardiomyopathy.
In summary, our findings represent the first proof-of-concept that
RC bypass can alleviate pathological manifestations in a genetic
mouse model of a human mitochondrial disorder. While restoring
(e.g., viral delivery) or correcting (e.g., CRISPR/Cas9 genome edit-
ing) the mutated gene in the affected tissue is theoretically the most
efficient treatment strategy in monogenic diseases, and has shown
promise in animal models (Logan et al, 2014; Ohmori et al, 2017),
this requires gene-specific tools and is only under development for
mtDNA mutations. Therefore, as an enzyme that can potentially
alleviate cIII or cIV blockade due to a wide variety of mutations,
AOX is worth further preclinical investigations, e.g., using viral
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delivery to the affected tissues in mouse models. Such experiments
should shed light on the possible immunological adverse effects
associated with the introduction of a non-mammalian protein into
juvenile or adult tissues. Alternatively, there is suggestive evidence
that beneficial cIII bypass-like effects can be achieved pharmacologi-
cally, for example with vitamin K2 (Vos et al, 2012) or methylene
blue (Atamna et al, 2008). Our results urge the search for novel
pharmacological bypass strategies potentially translatable to
patients. Finally, the AOX transgenic mice provide an excellent tool
to dissect the mechanisms underlying the wide variety of manifesta-
tions in mitochondrial disorders, the understanding of which is a
prerequisite for the development of novel therapies.
Materials and Methods
Animal breeding and husbandry
Heterozygous knock-in (Bcs1lc.A232G) mice in the C57BL/6JCrl (RRID:
IMSR_JAX:000664) background and AOX transgenic mice (Szibor
et al, 2017) were maintained in the animal facilities of University of
Helsinki, Finland. All mice were housed in individually ventilated
cages with 12-h light/12-h dark cycle at a temperature of 22–23°C,
and water and food (2018 Teklad global 18% protein rodent diet,
Envigo) available ad libitum. The animal studies were approved by
the animal ethics committee of the State Provincial Office of Southern
Finland (ESAVI/6142/04.10.07/2014 and ESAVI/6365/04.10.07/
2017) and were performed according to FELASA (Federation of
Laboratory Animal Science Associations) guidelines.
Bcs1lc.A232G homozygotes survive to over P150 in the C57BL/
6JCrl background (Purhonen et al, 2017). The two mouse strains
were crossed to generate double heterozygous mice, which were
backcrossed to the C57BL/6JCrl background for several generations.
Wild-type or Bcs1l heterozygous animals, littermates whenever
possible, were used as wild-type (WT) controls. Mice carrying a
single copy of the AOX transgene (AOX mice), littermates whenever
possible, were used as a second control group. Both genders were
used in the experiments and were not separated unless separate
analysis for males and females is indicated in Results. Genotyping
for the Bcs1l mutation and AOX transgene was performed as
described (Leve´en et al, 2011; Szibor et al, 2017).
Mouse health was monitored by manual behavioral scoring and
weighing according to the ethical permit and as described elsewhere
(Rajendran et al, 2016; Purhonen et al, 2017). The time points for
assessments were chosen to verify early and late-onset manifesta-
tions: growth and survival data from weaning on, whole-body meta-
bolism and DEXA data between 10 and 14 weeks of age (at German
Mouse Clinic), presymptomatic cardiac data at 5 months (P150),
end-stage disease for GRAC mice at 6–7 months (P200), and survival
and tissue histology of surviving GROX mice at up to 22 months
(P680). The total number of experimental mice used in this study
was 301.
Assessment of body composition and whole-body metabolism
At the German Mouse Clinic (GMC), the mice were maintained from
8 weeks of age until sacrificing at week 21 according to the GMC
housing conditions (www.mouseclinic.de) and German laws. All tests
were approved by the responsible authority of the Regierung von
Oberbayern. Twenty mice per genotype (WT, AOX, GRAC, and
GROX), 10 mice per gender, were phenotyped between ages P56 and
P112. The determination of energy expenditure by indirect calorime-
try was performed at P77. Dual-energy X-ray absorptiometry (DEXA)
was used to measure bone density, fat mass, and lean mass at P98.
Salt provocation and antioxidant administration
Powdered chow (2018 Teklad global 18% protein, Envigo) was
supplemented to contain 6% NaCl (w/w), moistened, and manually
compressed into pellets. The pellets were air dried for 24 h and
stored frozen. Control diet was prepared similarly but without the
addition of NaCl. The NaCl-supplemented chow was administered
ad libitum from P150 onwards. For antioxidant feeding, drinking
water was supplemented with 0.50 mM mitoquinol mesylate
(mitoQ, a kind gift from MitoQ Ltd, New Zealand) starting from
P150.
Echocardiography
The cardiac dimensions and ejection volume of mice were measured
by using Vevo 2100 imaging system (Fujifilm). B-mode and M-mode
were used to measure left ventricle dimensions, and the average
values were used for analysis.
Clinical chemistry and urine analysis
Alanine aminotransferase and alkaline phosphatase were measured
from plasma, and albumin and creatinine from urine samples using
Siemens ADVIA1650 analyzer. For urine collection, the mice were
kept in metabolic cages for 24 h under 12-h/12-h light/dark cycle.
Other urine analyses were performed by pipetting 15 ll of urine per
each test area on human urine strips (Combur10 Test UX, Roche),
followed by reading of the values in Urisys 1100 urine analyzer
(Roche).
Sample collection
For end point sacrificing and sample collection, the mice were not
fasted for longer than 2–3 h due to the hypoglycemia associated
with the mutant phenotype. All samples were collected at the same
time of the day during the light period of the mice. The mice were
anesthetized with pentobarbital, blood was collected into Li-heparin
tubes by cardiac puncture, and plasma was separated. Organs were
immediately dissected, and snap-frozen in liquid nitrogen or
immersed in 10% buffered formalin solution. Approximately 1 mm3
pieces of tissue were fixed in 1.5% glutaraldehyde and 1.5%
paraformaldehyde in 0.1 M So¨rensen buffer pH 7.2 for electron
microscopy. Brains (n = 6 per genotype at P200; n = 8 for AOX
and n = 10 for GROX at P600) were immersion-fixed in 4%
paraformaldehyde in 0.1 M sodium phosphate buffer pH 7.4 for
48 h followed by cryoprotection in 30% sucrose/0.05% sodium
azide in 50 mM Tris-buffered saline (TBS). Frozen coronal sections
(40 lm) were cut through cerebrum, while cerebella were cut sagit-
tally and stored in cryoprotectant solution as described (Tegelberg
et al, 2017). Blood glucose and lactate levels were measured using
commercial quick sticks and meters (Freestyle lite and Lactate Pro
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LT-1710). In living animals, the ventral tail artery was punctured
under light isoflurane anesthesia to measure glucose and lactate.
Histology and electron microscopy
Tissue sections were stained with standard methods to assess general
histology (hematoxylin–eosin) and fibrosis (Sirius Red). The area
stained by Sirius Red was quantified using ImageJ software (National
Institutes of Health, Bethesda, MD, USA) from 5 to 10 random fields.
Tissues were prepared for transmission electron microscopy using stan-
dard methods and examined in a Philips/FEI CM 100 BioTWIN trans-
mission electron microscope (Hillsboro, OR) at 60 kV. Images were
captured in side-mounted Olympus Veleta camera (Center Valley, PA)
with a resolution of 2,048 × 2,048 pixels (2k × 2k).
Immunohistochemistry
One-in-twelve series of free-floating cryosections were stained as
previously described (Bible et al, 2004). Primary antibody against
glial fibrillary acidic protein (GFAP: Z0334, DAKO, Agilent Tech-
nologies) diluted 1:4,000 in 10% normal serum in TBS-T was
incubated overnight at 4°C. Standard paraffin sections were
immunostained with primary antibodies against Ki67, cleaved
caspase-3, and 4-HNE (see Appendix Table 3), using Vectastain Elite
peroxidase reagents (Vector Laboratories) and standard protocols.
Western blot analyses
Frozen tissues were homogenized in RIPA buffer (50 mM Tris, pH 8,
150 mM NaCl2, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS) with protease inhibitors (Complete mini, Roche). Protein concen-
tration was measured using Bradford reagent (Bio-Rad). Approxi-
mately 10 lg of protein per lane was run on Mini-PROTEAN
StainFree© precast gradient gels (Bio-Rad). StainFree© dye was acti-
vated by UV light for one minute and proteins transferred to PVDF
membrane using Trans-Blot Turbo Transfer System (Bio-Rad). The fil-
ters were then imaged for total protein, blocked with 5% milk powder
in TBST, and stained with primary antibodies (Appendix Table S3).
Appropriate HRP-conjugated secondary antibodies and enhanced
chemiluminescence were used for the detection. Band intensities, as
recorded with ChemiDoc MP digital imager (Bio-Rad), were normal-
ized to total protein.
Isolation of mitochondria
Liver and kidney samples were minced with scissors and then
homogenized with a teflon-glass potter homogenizer containing
homogenization buffer (225 mM mannitol, 75 mM sucrose, 10 mM
Tris–HCl, 1 mM EGTA, 1 mg/ml albumin, and pH set to 7.4 at
+4°C). For respirometry, a crude mitochondrial fraction was
obtained by a two-step differential centrifugation (10 min at 800 g
and 10 min at 7,800 g). For other assays, differential centrifugation
was continued, including a 19% Percoll solution (GE Healthcare),
and the mitochondria were stored as pellets at 80°C. Heart mito-
chondria were isolated similarly, but the tissue was minced in
trypsin–EDTA solution (Thermo Scientific). Trypsin was inactivated
with fetal bovine serum and removed before homogenization. All
steps were carried at 0–4°C.
Blue native gel electrophoresis
Digitonin-solubilized mitochondria were prepared and subjected to
BNGE as described (Davoudi et al, 2014).
Respirometry
Oxygen consumption by isolated mitochondria was measured polaro-
graphically in Mir05 buffer (110 mM sucrose, 60 mM lactobionic
acid, 20 mM taurine, 20 mM HEPES, 10 mM KH2PO4, 3 mM MgCl2,
0.5 mM EGTA, and 1 g/l fatty acid free bovine serum albumin, pH
7.1) in a 2-ml chamber (OROBOROS Instruments). Sample,
substrates, inhibitors, and uncouplers were injected in following
order: (i) 1 mM malate, 5 mM pyruvate and 5 mM glutamate; (ii)
sample; (iii) 1.25 mM ADP; (iv) 10 lM cytochrome c; (v) 10 mM
succinate; (vi) 100 lM propyl gallate; (vii) 1 lg/ml oligomycin A;
(viii) carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP) titration to maximum respiration; (ix) 0.5 lM rotenone; and
(x) 1 lg/ml antimycin A. Complex IV activity was measured using
2 mM ascorbate and 0.5 mM N,N,N0,N0-tetramethyl-p-phenylenedia-
mine (TMPD) as substrates. Chemical and oxygen-dependent TMPD
auto-oxidation was determined after addition of 10 mM sodium
azide.
Mitochondrial H2O2 emission
The oxygraph was equipped with a fluorometer and set for Amplex
Red/horseradish peroxidase (HRP) assay to measure mitochondrial
H2O2 emission simultaneously with respirometry (Makrecka-Kuka
et al, 2015). To validate the assay, HRP-independent and catalase-
insensitive conversion of Amplex Red to the fluorescent resorufin
was initially tested. Liver and kidney, but not heart, mitochondria
possessed high rate of HRP-independent artificial Amplex Red oxida-
tion due to presence of mitochondrial carboxylesterases (Miwa et al,
2016). This signal was inhibited by adding 100 lM phenylmethyl-
sulfonyl fluoride. Final assay conditions in Mir05 buffer were 10 lM
Amplex Ultra Red (Invitrogen), 1 U/ml HRP, 6 U/ml superoxide
dismutase, 100 lM PMSF (for liver and kidney), and substrates for
cI- and cII-linked respiration as described in the previous chapter.
The assay was calibrated with a 0.4 nmol bolus of H2O2 in every
respiratory state for which results are reported. As a background for
heart and kidney mitochondria, the rate of fluorescence was
recorded when mitochondria were kept without any substrates. For
liver mitochondria, background was taken as a catalase-insensitive
(700 U/ml) fluorescence flux.
Enzyme activity and lipid peroxidation assays
The activity of cIII in isolated mitochondria was measured using a
spectrophotometric assay as described previously (Davoudi et al,
2014). Aconitase activity (MAK051, Sigma) and urinary isopros-
tanes (EA85, Oxford Biomedical Research) were measured using
the indicated commercial kits. Carbonylated proteins were
labeled on-filter with 2,4-dinitrophenylhydrazine (phosphoric
acid solution, 42215, Sigma-Aldrich) and detected with anti-dini-
trophenol antibody (Oxidized Protein Western Blot Kit, ab178020,
Abcam) as described (Colombo et al, 2016). Nitrites in heart tissue
were measured using Griess reagent (03553, Sigma-Aldrich).
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Isoprostanes were quantified from urine using a commercial ELISA
kit (ab175819, Abcam).
Transcriptomics
For RNA sequencing, rRNA was removed and the sequencing
libraries were prepared using Illumina TruSeq Stranded Total RNA
Library Prep Kit with Ribo-Zero Human/Mouse/Rat. Libraries were
sequenced on Illumina NextSeq 500 instrument using 75 bp kit.
Adapter sequences and low-quality reads were removed from the
data using cutadapt (Martin, 2011), and data were further screened
for remaining rRNA reads using SortMeRNA (Kopylova et al, 2012).
The data were mapped to M. musculus genome GRCm38.p4 using
STAR (Dobin et al, 2013). The original genome sequence and anno-
tation were augmented with sequence and annotation for AOX.
Count data were processed in R using GenomicFeatures and
GenomicAlignments (Lawrence et al, 2013), and the differential
expression analysis was carried out using DESeq2 (Love et al,
2014). PCA plots were generated using ClustVis online tool (www.b
iit.cs.ut.ee/clustvis).
Pathway enrichment analysis
Enrichment analyses were performed using filtered gene sets
(|FC| > 1.5, P < 0.05) against Reactome database using www.mouse
mine.org. To visualize pathway changes, heat maps were generated
by Gitool.2.3.1 with WT mean-centered Z-score values and gene
mapping for selected pathways as described (Gundem & Lopez-
Bigas, 2014; Perez-llamas & Lopez-Bigas, 2011). Pathway heat maps
were generated based on Z-score, showing upregulation (brown
color) and downregulation (blue color) of each pathway. P-values
for group comparison (labeled 1, 2, and 3) were calculated using
one-way ANOVA followed by selected comparisons and the
Benjamin–Hochberg FDR correction.
Metabolomics
Targeted quantitative metabolomics covering 116 metabolites was
performed using capillary electrophoresis–mass spectrometry (CE-
TOMFS and CE-QqQMS) at Human Metabolome Technologies Inc.,
Japan (http://humanmetabolome.com/en/). Details of the protocol
are available upon request. We omitted the AOX group in the meta-
bolomics since ectopic AOX was shown to be inert in healthy wild-
type mice (Szibor et al, 2017).
Statistics (excluding transcriptomics)
For normally distributed data, one-way ANOVA followed by
Tukey’s test or by selected comparisons using t-tests with Welch’s
correction was used. Normality of data was assessed by the
d’Agostino–Pearson omnibus normality test, and equality of vari-
ances by Bartlett’s test. Data not compatible with parametric tests
were assessed by Kruskal–Wallis and Mann–Whitney U-tests.
Survival curves were analyzed using log-rank Mantel–Cox test.
GraphPad Prism 7 software (GraphPad Software Inc., La Jolla, CA,
USA) was used for the statistical analyses. Group sizes (n) and the
statistical tests used are described in figure legends, and exact
P-values are shown in the graphs.
Data availability
Additional raw data and detailed protocols are available from the
authors upon request. Transcriptomics data have been deposited to
ArrayExpress database at EMBL-EBI under the accession ID
E-MTAB-7416 (https://www.ebi.ac.uk/arrayexpress/experiments/E-
MTAB-7416).
Expanded View for this article is available online.
The paper explained
Problem
Mitochondrial diseases are genetic disorders of energy metabolism
that can affect any one or several organs of the body, including skele-
tal muscle, heart, brain, and visceral organs. Nowadays, early diagno-
sis of mitochondrial disease is often possible using modern molecular
genetics, but treatment options remain scarce. Mutations in the BCS1L
gene are the most common cause of mitochondrial diseases affecting
the respiratory chain complex III (cIII). GRACILE syndrome (Growth
Restriction, Aminoaciduria, Cholestasis, liver Iron overload, Lactic
acidosis, and Early death), with neonatal lethality, is the most severe
of them. Due to the strikingly similar disease in all GRACILE syndrome
patients, Prof. Fellman’s group previously introduced the underlying
missense mutation (Bcs1lc.A232G, Bcs1lp.S78G) into mice. This mouse
model faithfully recapitulates most of the symptoms of the patients.
In search for novel strategies to alleviate cIII deficiency-related pathol-
ogy, we crossed the Bcs1lc.A232G mice with transgenic mice expressing
alternative oxidase (AOX), a mitochondrial inner membrane enzyme
that can bypass respiratory electron flow blockade when the quinol
oxidation capacity of cIII is compromised.
Results
Mice homozygous for the Bcs1lc.A232G mutation survived approxi-
mately 200 days and died of dilating cardiomyopathy, a novel late-
onset phenotype in the C57BL/6JCrl background. In contrast, the
homozygotes carrying the AOX transgene lived approximately
600 days and never developed the cardiomyopathy. AOX also amelio-
rated the severe kidney disease and focal astrogliosis of the brain in
the homozygotes. Surprisingly, AOX did not correct the liver disease,
poor growth, and loss of white fat, suggesting different disease
mechanism in different tissues. AOX corrected the abnormal ultra-
structure of mitochondria and mitochondrial respiration in those
tissues, in which the tissue pathology was alleviated. Heart and
kidney mitochondria from the homozygotes showed elevated reactive
oxygen species (ROS) production, but analyses of ROS damage
suggested that the beneficial effects of AOX were not ROS-related.
Instead, we found that AOX normalized cardiac gene expression
related to nitric oxide metabolism and signaling, a major modulator
of cardiovascular functions. We conclude that AOX efficiently
prevented tissue pathology in the Bcs1l mutant mouse model of cIII
deficiency by restoring respiration, preferably in the most highly
oxidative tissues such as heart.
Impact
Our study in the patient mutation knock-in model of cIII deficiency is
the first proof-of-concept that bypass of the cIII-cIV segment of the
respiratory electron transfer can alleviate pathological manifestations
in a physiologically relevant genetic mouse model of a human mito-
chondrial disorder. These findings highlight the potential of AOX as a
tool to unravel disease mechanisms, and also urge further studies of
AOX in preclinical models, e.g., using viral delivery to the affected
tissues in mouse models, as well as studies to search for novel phar-
macological bypass strategies potentially translatable to patients.
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